<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIMS: <z:e sem="disease" ids="C0282207" disease_type="Disease or Syndrome" abbrv="">Cronkhite-Canada syndrome</z:e> (CCS) is a noninherited condition, associated with high morbidity, and characterized by gastrointestinal <z:e sem="disease" ids="C0018552" disease_type="Neoplastic Process" abbrv="">hamartomatous</z:e> <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e>, <z:hpo ids='HP_0001596'>alopecia</z:hpo>, <z:hpo ids='HP_0008404'>onychodystrophy</z:hpo>, <z:mp ids='MP_0001188'>hyperpigmentation</z:mp>, and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> features may respond to immunosuppressive therapy, but little is known about the etiology </plain></SENT>
<SENT sid="2" pm="."><plain>An autoimmune origin has been suggested but not proved </plain></SENT>
<SENT sid="3" pm="."><plain>From a retrospectively selected cohort, we evaluated clinicopathologic features, including immunostaining for IgG4 (an antibody associated with <z:hpo ids='HP_0002960'>autoimmunity</z:hpo>), and therapeutic outcomes in a cohort of CCS patients to provide further insights into this disease </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Cases included 14 consecutive CCS patients seen at the Mayo Clinic on whom tissue and follow-up were available </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> histology was reviewed by an expert gastrointestinal pathologist </plain></SENT>
<SENT sid="6" pm="."><plain>Immunostaining for IgG4 was performed on 42 <z:mpath ids='MPATH_491'>polyps</z:mpath> from CCS cases and on control tissues, including 46 histologically similar <z:hpo ids='HP_0010566'>hamartomas</z:hpo> [from <z:e sem="disease" ids="C0345893" disease_type="Neoplastic Process" abbrv="JPS|JIP|PJI">juvenile polyposis syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JPS</z:e>)] and 20 <z:mpath ids='MPATH_458'>normal</z:mpath> mucosae (six stomach, three small bowel, and 11 colon) </plain></SENT>
<SENT sid="7" pm="."><plain>Clinical features and treatment outcomes were descriptive </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> CCS cases had both upper and lower gastrointestinal <z:mpath ids='MPATH_491'>polyps</z:mpath>; most had typical dermatologic features of <z:hpo ids='HP_0001596'>alopecia</z:hpo>, <z:mp ids='MP_0001188'>hyperpigmentation</z:mp>, and <z:hpo ids='HP_0008404'>onychodystrophy</z:hpo>; and most had evidence of <z:hpo ids='HP_0002243'>protein-losing enteropathy</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Ten patients (71%) had <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and 2 (14%) had <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>IgG4 immunostaining was positive (&gt;5 cells/HPF) in 52% of CCS <z:mpath ids='MPATH_491'>polyps</z:mpath> compared to 12% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JPS</z:e> <z:mpath ids='MPATH_491'>polyps</z:mpath> (P = 0.001); IgG4 staining was negative in <z:hpo ids='HP_0000001'>all</z:hpo> other control tissues </plain></SENT>
<SENT sid="11" pm="."><plain>Of 11 CCS patients treated with oral <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, 91% achieved remission </plain></SENT>
<SENT sid="12" pm="."><plain>Relapse was common with steroid tapering </plain></SENT>
<SENT sid="13" pm="."><plain>Five patients who initially responded to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> were maintained in remission on <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (2 mg/kg/day) with no relapse after a median of 4.5 years </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Immunostaining for the autoimmune-related IgG4 antibody is significantly increased in CCS <z:mpath ids='MPATH_491'>polyps</z:mpath> compared to disease and <z:mpath ids='MPATH_458'>normal</z:mpath> control tissues </plain></SENT>
<SENT sid="15" pm="."><plain>Furthermore, immunosuppression by <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> or long-term <z:chebi fb="2" ids="2948">azathioprine</z:chebi> may eradicate or lessen manifestations of CCS </plain></SENT>
<SENT sid="16" pm="."><plain>These histologic findings and treatment responses are consistent with an autoimmune mechanism underlying CCS </plain></SENT>
</text></document>